8-K: AmpliTech Group Secures $9M in Direct Offering, Boosts Executive Pay

AmpliTech Group, Inc. announced a $9 million registered direct offering and approved increased annual compensation for its key executives and independent directors.

Summary

• AmpliTech Group, Inc. entered into a Securities Purchase Agreement on January 26, 2026, for a registered direct offering.
• The company will sell 2,230,000 Units at $4.055 per Unit to five institutional investors, expecting gross proceeds of approximately $9,042,650.
• Each Unit consists of one share of common stock, one Series A Right (exercise price $5.00, expiring July 18, 2026), and one Series B Right (exercise price $6.00, expiring November 20, 2026).
• Moody Capital Solutions, Inc. will serve as the exclusive placement agent, receiving a 6.0% fee on gross proceeds from Unit sales and cash exercise of Series Rights, plus up to $15,000 in expenses.
• Company directors and executive officers are subject to a 60-day lock-up period on their securities following the offering's closing.
• Independent Director Agreements were executed on January 20, 2026, with Mr. Andrew Lee, Mr. Daniel Mazziota, and Mr. Shailesh Sonny Modi, providing annual compensation of 15,000 Restricted Stock Units and expense reimbursement for a one-year term.
• Annual compensation for key officers was approved, effective October 1, 2025: Fawad Maqbool (President and CEO/CTO) at $600,000, and Louisa Sanfratello (CFO) and Jorge Flores (COO) each at $350,000.

Sentiment

Score: 7

Explanation: The filing indicates a successful capital raise and strategic investments for growth, alongside strengthening corporate governance and management incentives. While dilution is a factor, the clear use of proceeds for expansion and operational improvements suggests a positive long-term outlook, assuming successful execution. The Nasdaq minimum bid price issue is a concern, but the capital raise could help address it.

Positives

• Successfully secured approximately $9.04 million in gross proceeds from a registered direct offering, strengthening the company's capital position.
• The capital raise is earmarked for strategic growth initiatives including scaling domestic manufacturing, R&D, product commercialization, vertical integration, supply-chain resilience, and strategic partnerships.
• Retention of three independent directors with one-year terms, indicating a commitment to corporate governance and oversight.
• Increased compensation for key executives and independent directors may help retain talent and align interests.

Negatives

• The offering includes Series A and Series B Rights, which, if exercised, could lead to further dilution for existing shareholders.
• A 6.0% placement agent fee on gross proceeds, plus expenses, will reduce the net proceeds from the offering.
• The lock-up agreement for directors and executive officers is relatively short at 60 days, potentially allowing for sales shortly after the offering.

Risks

• Dilution risk for existing shareholders from the issuance of 2,230,000 common shares and potential future exercise of Series A and Series B Rights.
• Market price volatility of common stock due to potential future sales by purchasers or hedging activities.
• The company's financial statements for the fiscal year ended December 31, 2025, are not yet finalized, and results may differ from expectations.
• The company is currently not in compliance with Nasdaq's minimum bid price requirement.
• Risks associated with the independent contractor status of directors, including tax obligations and lack of employee benefits.
• Potential for legal disputes related to non-solicitation, confidentiality, and non-competition clauses in director agreements.

Future Outlook

The company intends to use the net proceeds from the offering to scale domestic manufacturing and operations, advance R&D and product commercialization, deepen vertical integration and supply-chain resilience, engage in strategic partnerships, support corporate growth initiatives, and for working capital and general corporate purposes.

Management Comments

• The company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arms length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
• The company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers purchase of the Securities.
• The company further represents to each Purchaser that the Company's decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

Industry Context

The capital raise and strategic allocation of funds towards R&D, manufacturing, and supply chain resilience suggest AmpliTech Group is positioning itself for growth and competitive advantage in its sector, potentially in response to or in anticipation of evolving market demands and supply chain challenges. The focus on domestic manufacturing and vertical integration aligns with broader industry trends seeking to reduce reliance on external, potentially volatile, supply chains.

Comparison to Industry Standards

• The 6.0% placement agent fee is within the typical range for registered direct offerings of this size, which can vary from 5% to 7% depending on market conditions and the complexity of the deal.
• The 60-day lock-up period for insiders is on the shorter side compared to traditional IPO lock-ups (typically 90-180 days), but not uncommon for follow-on offerings or direct placements.
• The RSU compensation for independent directors is a common practice to align their interests with shareholders, though the specific number of units would need to be benchmarked against peer companies' market capitalization and director responsibilities.

Management Changes

Corporate Governance

Legal Proceedings

• No new legal proceedings or regulatory matters are explicitly disclosed as pending or threatened against the company in this filing, beyond general representations that no such actions would result in a Material Adverse Effect.

Related Party Transactions

• None beyond standard compensation and director agreements as disclosed, which include annual salaries for executives and Restricted Stock Units for independent directors, along with expense reimbursements.

Stakeholder Impact

• Shareholders: Potential dilution from the offering and future exercise of rights; increased capital for growth initiatives could lead to long-term value creation; increased executive compensation could be viewed positively (retention) or negatively (cost).
• Employees: No direct impact mentioned, but strategic growth initiatives could lead to job creation or stability.
• Customers/Suppliers: Strategic investments in manufacturing, R&D, and supply chain resilience could lead to improved products, services, and reliability.
• Creditors: The capital raise strengthens the company's financial position, potentially reducing credit risk.

Next Steps

• Closing of the registered direct offering on or about January 27, 2026.
• Filing of the Current Report on Form 8-K, including Transaction Documents as exhibits.
• Application to Nasdaq for listing of the newly issued shares and rights shares.
• Continued efforts to maintain Nasdaq listing compliance, particularly regarding the minimum bid price requirement.
• Performance of services by independent directors for a one-year term.
• Potential exercise of Series A Rights by July 18, 2026, and Series B Rights by November 20, 2026.

Key Dates

Recommendation

The capital raise provides necessary funding for strategic growth initiatives, which is a positive. However, the immediate dilution from the offering and potential future dilution from the Series Rights, combined with the existing Nasdaq minimum bid price compliance issue, create a mixed outlook. While the company is investing in its future, the short-term stock performance may be impacted by these factors. A 'hold' recommendation reflects the balance between growth potential and current risks, advising investors to monitor execution of strategic plans and resolution of compliance issues.

Keywords

AmpliTech Group, AMPG, Registered Direct Offering, Equity Raise, Common Stock, Series Rights, Restricted Stock Units, Executive Compensation, Independent Directors, Corporate Governance, Capital Raise, SEC Filing, Nasdaq